Literature DB >> 8740102

Diminished T lymphocyte proliferative response to polyclonal mitogens in acute brucellosis patients.

M Rodriguez-Zapata1, M Alvarez-Mon, I Salmeron, A Prieto, L Manzano, O J Salmeron, J Carballido.   

Abstract

T lymphocytes from 21 untreated patients with acute brucellosis were tested for their proliferative response to polyclonal mitogens. The purified T lymphocytes from these patients showed a defective proliferative response to plant lectins and anti CD3 monoclonal antibodies with respect to the response observed in T lymphocytes from 21 healthy controls (p < 0.05). This defective proliferative response was not corrected by the exogenous addition of interleukin-2 or tumor necrosis factors alpha or beta to the culture medium. After antibiotic therapy, the proliferative response to the mitogens in T lymphocytes was found to be similar to that of the healthy controls (p > 0.05), and significantly higher than that found before treatment (p < 0.05). It was concluded that T lymphocytes from acute brucellosis patients have a defective proliferative response to membrane mitogenic signals, which disappears when the patients are cured after antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740102     DOI: 10.1007/bf01713314

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Impaired activity of natural killer cells in patients with acute brucellosis.

Authors:  I Salmerón; M Rodríguez-Zapata; O Salmerón; L Manzano; S Vaquer; M Alvarez-Mon
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

Review 2.  Functional and molecular aspects of human T lymphocyte activation via T3-Ti and T11 pathways.

Authors:  A Alcover; D Ramarli; N E Richardson; H C Chang; E L Reinherz
Journal:  Immunol Rev       Date:  1987-02       Impact factor: 12.988

3.  Regulation of the alternative pathway of T cell activation by anti-T3 monoclonal antibody.

Authors:  D A Fox; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

4.  Lymphotoxin is an important T cell-derived growth factor for human B cells.

Authors:  J H Kehrl; M Alvarez-Mon; G A Delsing; A S Fauci
Journal:  Science       Date:  1987-11-20       Impact factor: 47.728

5.  In vitro interactions of purified cloned human interferons on NK cells: enhanced activation.

Authors:  S Targan; N Stebbing
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

6.  Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes.

Authors:  J C Reed; J D Alpers; P C Nowell; R G Hoover
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 7.  Macrophages and Brucella.

Authors:  C L Baldwin; A J Winter
Journal:  Immunol Ser       Date:  1994

8.  T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy.

Authors:  A Haregewoin; T Godal; A S Mustafa; A Belehu; T Yemaneberhan
Journal:  Nature       Date:  1983-05-26       Impact factor: 49.962

9.  Immune interferon: a pleiotropic lymphokine with multiple effects.

Authors:  G Trinchieri; B Perussia
Journal:  Immunol Today       Date:  1985-04

10.  Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis.

Authors:  Z Toossi; M E Kleinhenz; J J Ellner
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  7 in total

1.  Defective reactive oxygen metabolite generation by macrophages from acute brucellosis patients.

Authors:  M Rodriguez-Zapata; E Reyes; L Sanchez; A Espinosa; J Solera; M Alvarez-Mon
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

2.  A B lymphocyte mitogen is a Brucella abortus virulence factor required for persistent infection.

Authors:  Juan Manuel Spera; Juan Esteban Ugalde; Juan Mucci; Diego J Comerci; Rodolfo Augusto Ugalde
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-19       Impact factor: 11.205

3.  Key immunity characteristics of diverse stages of brucellosis in rural population from Inner Mongolia, China.

Authors:  Yongzhang Zhu; Li Shi; Yige Zeng; Dongri Piao; Yingbo Xie; Juan Du; Meng Gao; Wei Gao; Junli Tian; Jun Yue; Min Li; XiaoKui Guo; Yufeng Yao; YaoXia Kang
Journal:  Infect Dis Poverty       Date:  2022-06-04       Impact factor: 10.485

4.  Liver involvement in patients with brucellosis: results of the Marmara study.

Authors:  D Ozturk-Engin; H Erdem; S Gencer; S Kaya; A I Baran; A Batirel; R Tekin; M K Celen; A Denk; S Guler; M Ulug; H Turan; A U Pekok; G Mermut; S Kaya; M Tasbakan; N Tulek; Y Cag; A Inan; A Yalci; C Ataman-Hatipoglu; I Gonen; A Dogan-Celik; F Bozkurt; S Gulsun; M Sunnetcioglu; T Guven; F Duygu; E Parlak; H Sozen; S Tosun; T Demirdal; E Guclu; O Karabay; N Uzun; O Gunal; H Diktas; A Haykir-Solay; A Erbay; C Kader; O Aydin; A Erdem; N Elaldi; A Kadanali; Z Yulugkural; L Gorenek; M Altındis; S Bolukcu; C Agalar; N Ormeci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-21       Impact factor: 3.267

5.  Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2.

Authors:  Paula Barrionuevo; Juliana Cassataro; M Victoria Delpino; Astrid Zwerdling; Karina A Pasquevich; Clara García Samartino; Jorge C Wallach; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

Review 6.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

Review 7.  Brucellosis in patients infected with the human immunodeficiency virus.

Authors:  S Moreno; J Ariza; F J Espinosa; D Podzamczer; J M Miró; A Rivero; M Rodríguez-Zapata; J Arrizabalaga; R Mateos; F Herrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.